Research programme: small molecule therapeutics - Enveda Bioscience
Latest Information Update: 27 Dec 2023
Price :
$50 *
At a glance
- Originator Enveda Biosciences
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 21 Dec 2023 Preclinical trials in Skin disorders in USA (Topical) (Enveda Bioscience pipeline, December 2023)
- 26 Dec 2022 Preclinical trials in Pain in USA (unspecified route), prior to December 2022 (Enveda Biosciences pipeline, December 2022)
- 21 Dec 2022 Enveda Biosciences announces its intention to declare multiple clinical candidates in 2023